Work

Supplementary Figures 1 - 2 from A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

Year: 2023

Type: supplementary-materials

Abstract: Figure S1. EPO and plasma chemokine expression following treatment with ARRY-614 at 1200 mg QD. Figure S2. Comparison of EPO in IWG2006 Responders and Non-Responders.

DOI: 10.1158/1078-0432.22461647

Authors: Guillermo Garcia-Manero, Hanna J. Khoury, Elias Jabbour, Jeffrey Lancet, Shannon L. Winski, LouAnn Cable, Selena Rush, Lara Maloney, Grant Hogeland, Mieke Ptaszynski, Monica Cabrero Calvo, Zach Bohannan, Alan List, Hagop Kantarjian, Rami Komrokji

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361885310

Cites:

Cited by:

Related to: 10